Kesehatan

Shanghai Upper Bio-Tech Pharma Co., Ltd.

Shanghai Upper Bio-tech Co., Ltd. is located in Zhangjiang Science City Modern Medical Device Park in Shanghai. Our company specializes in the development, production, sales, and big data services of internet-enabled intelligent point-of-care testing (iPOCT) products. Upper holds over 400 intellectual property rights and has participated in more than 20 national and provincial-level major projects. It has led the publication of three industry monographs, including POCT, iPOCT, and IVD +(Big Data Smart Diagnosis). Our company has received seven scientific and technological awards, 10+ honors such as National Key New Products and Shanghai High-Tech Achievement Transformation Projects, and contributed to five national, industrial, and group standards. Designated as a National Specialized and Sophisticated Small Giant Enterprise, a National Intellectual Property Demonstration Enterprise, and home to a Postdoctoral Research Workstation, Shanghai Engineering Technology Research Center for Point-of-Care Testing, and Shanghai Enterprise Technology Center, Upper is a leader in innovation. Focused on rapid quantitative testing for cardiovascular diseases, diabetes nephropathy, autoimmune disorders, reproductive health, infectious diseases, and inflammatory infections, Our company has launched over 60 instrument and reagent products. These are used in over 1,000 medical institutions nationwide and internationally, serving tens of millions of patients annually. Through publications and industry initiatives, Our company introduced the "iPOCT" concept centered on precision, automation, cloud-based services, and sharing, along with a "smart diagnosis + health big data" model. It also pioneered the "3D Innovation(Instrument + Reagent + AI)" strategy integrating instruments, reagents, and cloud quality control. Listed on the National Equities Exchange and Quotations (NEEQ) under the code 873758 and entering the Innovation Tier, Upper leverages Shanghai Free Trade Zone policies and Zhangjiang’s biopharmaceutical ecosystem. The company aims to accelerate synergies between capital, technology, and markets, establishing itself as a premier brand in China’s digital diagnostic sector while contributing to Shanghai’s and China’s strategic goals.

Galeri perusahaan

1 / 2

Produk & keunggulan

ExoFaster-500 Exosome Automated Extraction Platform

The ExoFaster is a fully automated exosome extraction platform based on size-exclusion chromatography (SEC). It is designed for the automated isolation and purification of small extracellular vesicles (sEVs) from cell culture supernatant, plasma, and other biological samples. The system flexibly processes 1–9 samples and completes nine samples in only 48 minutes, reducing manual operation while improving workflow standardization, reproducibility, and laboratory efficiency. The platform provides standardized extraction protocols, customizable programs, and automated cleaning procedures to support different research applications. Together with dedicated SEC columns, it delivers high-purity sEVs with well-preserved morphology and a predominant particle-size distribution of 40–150 nm, suitable for downstream analysis such as NTA, TEM, Western blotting, and other extracellular vesicle research.

Armada-500 Compact Fully Automated Integrated Biochemistry & Immunoassay Analyzer

The Armada-500 is a compact, fully automated integrated biochemistry and immunoassay analyzer enhanced with AI-powered intelligent algorithms, delivering up to 100 tests per hour. It supports multiple sample types and features intelligent liquid-level detection, automatic dilution determination, and alerts for sample probe blockage and abnormal air aspiration. These functions help reduce manual intervention and improve testing efficiency and operational reliability.

← Kembali ke direktori